| 1 |
35221690 | Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes. | 2022 |
1 |
| 2 |
33603500 | Novel Experimental Agents for the Treatment of Hypercholesterolemia. | 2021 |
1 |
| 3 |
34357325 | The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials. | 2021 Jul 20 |
1 |
| 4 |
31916186 | Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. | 2020 Feb |
2 |
| 5 |
32324598 | The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? | 2020 Jun |
1 |
| 6 |
30500603 | Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. | 2019 Jan |
1 |
| 7 |
30526168 | Mipomersen and its use in familial hypercholesterolemia. | 2019 Feb |
1 |
| 8 |
31111240 | Antisense Oligonucleotides Targeting Lipoprotein(a). | 2019 May 20 |
3 |
| 9 |
31449975 | A new dawn for managing dyslipidemias: The era of rna-based therapies. | 2019 Dec |
1 |
| 10 |
30293969 | Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects. | 2018 Dec |
1 |
| 11 |
26819195 | Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans. | 2016 Jan 27 |
2 |
| 12 |
27261867 | My Approach to the Patient With Familial Hypercholesterolemia. | 2016 Jun |
1 |
| 13 |
27578117 | Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. | 2016 Jul-Aug |
2 |
| 14 |
27678436 | Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country. | 2016 Sep-Oct |
1 |
| 15 |
27749370 | Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism. | 2016 Dec |
3 |
| 16 |
27919344 | JCL roundtable: Risk evaluation and mitigation strategy. | 2016 Nov - Dec |
1 |
| 17 |
28018102 | Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. | 2016 Dec 7 |
1 |
| 18 |
30695320 | [Familial Hypercholesterolemia and Its Related Molecules]. | 2016 Jun |
1 |
| 19 |
25398643 | The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations. | 2015 Jan |
1 |
| 20 |
25410046 | Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. | 2015 Jan |
1 |
| 21 |
25542072 | Genetic therapies to lower cholesterol. | 2015 Jan |
1 |
| 22 |
25670911 | The genetics of familial hypercholesterolemia and emerging therapies. | 2015 |
1 |
| 23 |
25911076 | Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. | 2015 Mar-Apr |
1 |
| 24 |
25922802 | New drugs for treating dyslipidemia: beyond statins. | 2015 Apr |
4 |
| 25 |
26370207 | Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia. | 2015 Oct |
1 |
| 26 |
26402926 | Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice. | 2015 Aug |
1 |
| 27 |
24632267 | The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. | 2014 May 20 |
1 |
| 28 |
24953393 | Hypolipidaemic drug treatment: yesterday is not gone yet, today is challenging and tomorrow is coming soon; let us combine them all. | 2014 |
1 |
| 29 |
25499943 | Liver histology during Mipomersen therapy for severe hypercholesterolemia. | 2014 Nov-Dec |
1 |
| 30 |
23013161 | Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. | 2013 Aug |
1 |
| 31 |
23129439 | LDL Lowering After Acute Coronary Syndrome: Is Lower Better? | 2013 Feb |
2 |
| 32 |
23314926 | Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis. | 2013 Apr |
1 |
| 33 |
23319054 | Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo. | 2013 Mar |
3 |
| 34 |
23461430 | Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. | 2013 Mar |
2 |
| 35 |
23839331 | Recent advances in the treatment of homozygous familial hypercholesterolaemia. | 2013 Aug |
1 |
| 36 |
23913122 | New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? | 2013 Dec |
1 |
| 37 |
24013058 | Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. | 2013 Dec 10 |
1 |
| 38 |
22301884 | Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins. | 2012 Apr |
1 |
| 39 |
22701100 | Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. | 2012 |
1 |
| 40 |
22799743 | Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. | 2012 Jul 30 |
1 |
| 41 |
23152839 | Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. | 2012 |
1 |
| 42 |
23226021 | Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. | 2012 |
1 |
| 43 |
21210756 | Mipomersen, an antisense apolipoprotein B synthesis inhibitor. | 2011 Feb |
1 |
| 44 |
21343632 | Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice. | 2011 May |
2 |
| 45 |
20425272 | Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. | 2010 Jan |
2 |
| 46 |
20508521 | Apolipoprotein B synthesis inhibition: results from clinical trials. | 2010 Aug |
1 |
| 47 |
20615897 | Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. | 2010 Nov |
2 |
| 48 |
21122677 | Novel therapies and new targets of treatment for familial hypercholesterolemia. | 2010 Sep-Oct |
1 |
| 49 |
19056355 | Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. | 2009 Mar 1 |
1 |
| 50 |
20129365 | Current strategies and recent advances in the therapy of hypercholesterolemia. | 2009 Dec 29 |
1 |